Abivax‘s latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, CEO Marc de Garidel told CNBC after months of intense takeover speculation. “Thanks to the cash we raised… We are in a position to have cash until the end of 2029, and…
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the drug’s future. Abivax stock was last trading up 34% at 111.7 euros. The move comes after it crashed…
Abivax is planning to raise money after releasing key trial data in June, its CEO told CNBC on Tuesday, signaling to potential buyers of the firm that it is in no rush to sell. Intense takeover rumors have surrounded the French biotech company for months, impacting the volatile stock that rose nearly 1,700% in 2025….
Vcg | Visual China Group | Getty Images Wall Street analysts guide investors with their research and useful insights, but some consistently outperform others with strong, accurate calls. TipRanks, a platform that tracks and ranks analysts based on the accuracy and success of their recommendations, has released its list of analysts who stood out in…
